Affordable Access

deepdyve-link
Publisher Website

High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.

Authors
  • Pham-Ledard, Anne
  • Beylot-Barry, Marie
  • Barbe, Coralie
  • Leduc, Marion
  • Petrella, Tony
  • Vergier, Béatrice
  • Martinez, Fabian
  • Cappellen, David
  • Merlio, Jean-Philippe
  • Grange, Florent
Type
Published Article
Journal
JAMA dermatology
Publication Date
Nov 01, 2014
Volume
150
Issue
11
Pages
1173–1179
Identifiers
DOI: 10.1001/jamadermatol.2014.821
PMID: 25055137
Source
Medline
License
Unknown

Abstract

This study confirms the high prevalence of MYD88 L265P mutation in PCLBCL-LT and shows its association with shorter survival. The clinical effect of MYD88 mutation activating the nuclear factor-κB pathway supports the use of targeted therapies at the time of relapse after conventional therapies.

Report this publication

Statistics

Seen <100 times